ライフサイエンスコーパス: nausea

1 was gastrointestinal adverse events such as nausea.

2 included mild diarrhea, abdominal pain, and nausea.

3 ll-grade adverse events were neutropenia and nausea.

4 events were headache, diarrhea, fatigue, and nausea.

5 n adverse events were headache, fatigue, and nausea.

6 ncrease in grade 3 to 4 toxicity, except for nausea.

7 stratified by sex and presence or absence of nausea.

8 observed even in subjects with little or no nausea.

9 ients) were headache, fatigue, diarrhea, and nausea.

10 n adverse events were headache, fatigue, and nausea.

11 most common AEs were fatigue, headache, and nausea.

12 th nivolumab included fatigue, pruritus, and nausea.

13 rk but are also associated with headache and nausea.

14 pain, upper respiratory tract infection, and nausea.

15 alopecia, diarrhoea, decreased appetite, and nausea.

16 of the patients were pruritus, fatigue, and nausea.

17 V were fatigue, anemia, gastroenteritis, and nausea.

18 nspecific symptoms of lethargy, fatigue, and nausea.

19 events were headache, fatigue, diarrhea, and nausea.

20 plus oxaliplatin (FOLFOX; cycle 1 mean grade nausea 1.1 [SD 1.0] vs 0.6 [0.7]; p<0.0001).

21 [1.70] at the 36-month follow-up; P = .07), nausea (1.69 [1.63] vs 0.77 [1.25]; P = .08), pain with

22 -5 Gastroparesis Clinical Symptom Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P =

23 iarrhoea (21 [47%]), fatigue (12 [27%]), and nausea (11 [24%]).

24 .8%), infusion-related reaction (20.5%), and nausea (11.4%).

25 included fatigue (21%), headache (20%), and nausea (12%).

26 0% and 11.1% vs 7.1% and 6.2% with placebo), nausea (12.4% and 9.1% vs 5.1% and 7.3%), and vomiting (

27 delpar 50 mg, and one on seladelpar 200 mg), nausea (13%; one patient on placebo, three on seladelpar

28 re diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increas

29 s, most commonly: fatigue (29%), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%), and arthra

30 28 [6%] patients in the moxifloxacin group), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [

31 well tolerated, with QTc prolongation (19%), nausea (16%), fatigue (14%), and constipation (14%) as t

32 rgent adverse events in all 32 patients were nausea (17 [53%]), diarrhoea (16 [50%]), and fatigue (16

33 adache (26% of patients), fatigue (21%), and nausea (17%).

34 e events were fatigue (48%), insomnia (19%), nausea (18%), and headache (16%).

35 ere fatigue (55%), abdominal pain (34%), and nausea (19%).

36 promethazine [P = .81], VAS [0-10 scale] for nausea, 2 [IQR, 1-5] vs 2 [IQR, 1-4], respectively [P =

37 Patients receiving erythromycin had nausea (20 [30%] vs 4 [6%]) and stomach cramps (15 [23%]

38 events were pyrexia (27 [42%] vs 11 [32%]), nausea (20 [31%] vs 7 [21%]), diarrhoea (19 [30%] vs 6 [

39 e fatigue (29; 13%), headache (27; 12%), and nausea (20; 9%).

40 The most common adverse events were nausea (21 [17%] of 122 patients), nasopharyngitis (18 [

41 ), infusion-related reaction (38 [21%]), and nausea (23 [13%]).

42 st common adverse events were fatigue (29%), nausea (23%), and headache (22%) in all patients and ane

43 ents were fatigue (51%), headache (36%), and nausea (23%).

44 aparib and placebo groups included low-grade nausea (24 [75%] of 32 patients vs two [40%] of five), f

45 ] of 49 patients), diarrhoea (27 [55%]), and nausea (25 [51%]).

46 rring more frequently with bicalutamide were nausea (26 [14%] vs 33 [17%]), constipation (23 [13%] vs

47 e most commonly reported adverse events were nausea (27%) and headache (23%).

48 quent treatment-emergent adverse events were nausea (31.0%), chills (23.8%), headache (21.4%), and in

49 24%] in the darunavir plus ritonavir group), nausea (31/242 [13%] vs 34/242 [14%]), and headache (17/

50 23%] of 240), fatigue (47 [20%] of 240), and nausea (32 [13%] of 240).

51 igue (51 patients, 23%), headache (44, 20%), nausea (32, 15%), and diarrhoea (21, 10%).

52 erved toxic effects were fatigue (39 [75%]), nausea (33 [63%]), diarrhoea (33 [63%]), and hypertensio

53 ents included diarrhea (54%), fatigue (50%), nausea (33%), and dyspnea (32%).

54 , with diarrhea (44%), blurred vision (41%), nausea (37%), and fatigue (30%) being the most commonly

55 g colitis) (64%), rash (58%), pyrexia (42%), nausea (38%), chills (36%), cough (33%), and fatigue (31

56 ies (diarrhea [46%], constipation [41%], and nausea [38%]) and grade 3/4 cytopenias (thrombocytopenia

57 most common drug-related adverse events were nausea (39 [7%] vs 18 [7%]), headache (16 [3%] vs 12 [5%

58 y more patients in the RMG group reported no nausea (39.6% [95% CI, 35.3%-44.1%] vs 30.7% [95% CI, 26

59 requent with orteronel-prednisone, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v

60 sensory neuropathy (78%), fatigue (44%), and nausea (44%), and were </= grade 2 for most patients.

61 dverse effects, predominantly fatigue (63%), nausea (44%), decreased appetite (37%), thrombocytopenia

62 and atazanavir groups; the most common were nausea (46 [19%] of 248 in the dolutegravir group vs 49

63 23 [35%]), mucositis (34 [53%] vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12

64 nts included mild gastrointestinal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]).

65 Grade 1 or 2 diarrhea (69%) and nausea (49%) were the most common treatment-emergent adv

66 Nausea (51.5%), fatigue (51.5%), pyrexia (42.4%), and dy

67 mptoms (ie, a great deal or a lot) including nausea, 52.3% (57 of 109), loss of appetite, 50.5% (49 o

68 y more patients in the RMG group reported no nausea (53.7% [95% CI, 49.2%-58.1%] vs 41.6% [95% CI, 37

69 alopecia (60 [74%] of 81 vs 44 [59%] of 75), nausea (56 [69%] vs 43 [57%]), neutropenia (40 [49%] vs

70 cluded fatigue (27%), neutropenia (12%), and nausea (6%).

71 The most common adverse events were nausea (6.4% and 2.0% in the lurasidone and placebo grou

72 astrointestinal-related disorders, primarily nausea (65 [12%] of 556 reported adverse events in the c

73 s included neutropenia (28%), diarrhea (7%), nausea (7%), fatigue (6%), and febrile neutropenia (4%).

74 lated adverse events included fatigue (70%), nausea (70%), anorexia (66%), and vomiting (49%), which

75 mon nonhematologic adverse events (AEs) were nausea (75%), fatigue (70%), anorexia (64%), vomiting (4

76 Es; the most frequent were anorexia (79.2%), nausea (75.5%), headache (60.4%), amnesia (58.5%), and >

77 nstrated manageable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), an

78 ncluded abdominal pain (in 18% of patients), nausea (8%), ascites (3%), fatigue (3%), gastric stenosi

79 eluxadoline, as compared with placebo, were nausea (8.1% and 7.5% vs. 5.1%), constipation (7.4% and

80 , ageusia (112 [22%]), diarrhoea (83 [17%]), nausea (80 [16%]), and fatigue (80 [16%]).

81 most common adverse events of any grade were nausea (85 [64%] of 132 patients in the gefitinib group

82 common reported gastrointestinal symptom was nausea (86 %).

83 roup were headache (17%), fatigue (16%), and nausea (9%).

84 of gastric emptying and vomiting, as well as nausea, abdominal pain, bloating, and early satiety comp

85 Secondary end points included nausea, abdominal pain, bloating, early satiety, as well

86 orded vomiting frequency and symptom scores (nausea, abdominal pain, postprandial fullness, and bloat

87 emetic prophylaxis reduces the likelihood of nausea among adult patients who are treated with high em

88 p versus three (5%) in the placebo group had nausea and 15 (17%) versus three (5%) had vomiting.

89 Mild nausea and asymptomatic increases in gamma-glutamyl tran

90 and fatal outcome, such as early symptoms of nausea and diarrhea, history of alcoholism or chronic lu

91 %); the most common AEs in either group were nausea and diarrhea.

92 vents with liraglutide were mild or moderate nausea and diarrhea.

93 quent adverse effects after eltoprazine were nausea and dizziness.

94 clusions and Relevance: For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, anti

95 omplaining of epigastric pain for a week and nausea and fever for a day presented to our emergency de

96 In Rome IV functional nausea and functional vomiting are now described.

97 2 nausea at 120 mg; G3 fatigue at 250 mg; G2 nausea and G4 thrombocytopenia at 350 mg; and G3 vomitin

98 epression-by-time interactions were seen for nausea and gas (P < .03).

99 ssociated with off-target effects, including nausea and gastrointestinal disturbance.

100 The most common adverse event was nausea and most common serious adverse event was worseni

101 AIMS: There are few effective treatments for nausea and other symptoms in patients with gastroparesis

102 In the rituximab group, nausea and skin rash during infusion were common; transi

103 on of patients in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3

104 ografin did not affect time to resolution of nausea and vomiting (64.5 vs 74.3 hours; P = 0.404) or c

105 ciated with the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely con

106 Chronic unexplained nausea and vomiting (CUNV) is a debilitating disease of

107 complications: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acu

108 tter physical functioning (P </= .001), less nausea and vomiting (P = .029 and .031, respectively) an

109 en before thyroidectomy reduce postoperative nausea and vomiting (PONV) in a randomized controlled tr

110 rbidities including migraines, postoperative nausea and vomiting (PONV), vertigo and morning sickness

111 Importance: Nausea and vomiting affects approximately 85% of pregnan

112 The ECS is involved in the control of nausea and vomiting and visceral sensation.

113 ids (dronabinol and nabilone), which include nausea and vomiting associated with chemotherapy and app

114 ple sclerosis (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in canc

115 her anti-emetic agents for the prevention of nausea and vomiting associated with moderately or highly

116 a randomized trial of patients with chronic nausea and vomiting caused by gastroparesis or gastropar

117 to reduce symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastropar

118 binoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in

119 l for the prevention of chemotherapy-induced nausea and vomiting during the 5-day (0-120 h) at-risk p

120 l for the prevention of chemotherapy-induced nausea and vomiting during the at-risk period (120 h) af

121 ritis in 13 patients (52%) and preceded by a nausea and vomiting episode in 2 patients (8%).

122 erious adverse events were gastrointestinal (nausea and vomiting in four participants during pregnanc

123 ist) for the prevention of acute and delayed nausea and vomiting in patients receiving chemotherapy.

124 efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetoge

125 , for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer after admini

126 nist, for prevention of chemotherapy-induced nausea and vomiting in patients with cancer after admini

127 ics are used to prevent chemotherapy-induced nausea and vomiting in patients with cancer.

128 current evidence on effective treatments for nausea and vomiting in pregnancy and hyperemesis gravida

129 The primary end points were control of both nausea and vomiting in the acute posttreatment period (f

130 .7 [3.3-10], respectively), and incidence of nausea and vomiting in the PACU (4 of 19 [21.1%] and 6 o

131 Chemotherapy-induced nausea and vomiting is a common side-effect of many anti

132 Hyperemesis gravidarum or severe nausea and vomiting of pregnancy affects women's physica

133 s with at least moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a min

134 chemotherapy with high chemotherapy-induced nausea and vomiting risk (32.4% [n = 106795]).

135 rtment with history of lower abdominal pain, nausea and vomiting since 2 days which was gradual in on

136 duration of hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of lif

137 a role for glucose levels in motion-induced nausea and vomiting, a finding that may provide insight

138 For radiation-induced nausea and vomiting, adjustments were made to anatomic r

139 penia, neutropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly wo

140 this technique on postoperative opioid use, nausea and vomiting, and pain scores.

141 GHS/QoL) scale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role fu

142 to hospital, but increases the occurrence of nausea and vomiting.

143 tients with low risk of chemotherapy-induced nausea and vomiting.

144 stratified by risk for chemotherapy-induced nausea and vomiting.

145 lastic agents or who experience breakthrough nausea and vomiting; a recommendation to administer dexa

146 horts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients with grade >

147 ellyfish, he experienced erythema, wheezing, nausea, and abdominal pain.

148 e associations with pain, burning sensation, nausea, and bloating scores.

149 vents were fatigue, diarrhea, muscle spasms, nausea, and bruising.

150 nimals associate a novel taste with visceral nausea, and demonstrate that there are two parallel memo

151 ession; nonhematologic AEs included fatigue, nausea, and diarrhea.

152 tment-emergent adverse events were headache, nausea, and dissociation; the last-mentioned was transie

153 Headache, anxiety, dissociation, nausea, and dizziness were the most common (>/=20%) trea

154 reported were insomnia, decreased appetite, nausea, and dry mouth.

155 ntly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported while patie

156 o 2 toxicities, especially thrombocytopenia, nausea, and elevation of liver enzymes.

157 includes five elements: sex, timing, origin, nausea, and erythrocytes.

158 Xerostomia, nausea, and fatigue occurred sporadically (<10%).

159 Most common adverse events were headache, nausea, and fatigue, occurring at similar frequencies in

160 ommon reported adverse events were headache, nausea, and fatigue.

161 ities including fever, respiratory distress, nausea, and flu-like symptoms.

162 a, grade 3 device-related infection, grade 2 nausea, and grade 1 fever), compared with nine patients

163 Vomiting, nausea, and headache were the only treatment-emergent ad

164 The most common adverse events were fatigue, nausea, and headache.

165 n adverse events included fatigue, headache, nausea, and insomnia.

166 s in the two studies were fatigue, headache, nausea, and insomnia.

167 st common adverse events (AEs) were fatigue, nausea, and peripheral edema (frequencies similar across

168 oup) were diarrhoea, injection-site nodules, nausea, and urinary tract infections.

169 such as asthenia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequen

170 st common adverse events (AEs) were fatigue, nausea, and vomiting.

171 ditory, olfactory and somatosensory stimuli, nausea, and vomiting.

172 ful disorders and specific symptoms of pain, nausea, and vomiting.

173 the third dose, he presented with headache, nausea, and vomiting; a brain magnetic resonance imaging

174 es, infection, anxiety/depression, diarrhoea/nausea, and weight gain.

175 notransferase (n = 2), diarrhea (n = 1), and nausea/anorexia (n = 1).

176 s, symptomatic adverse events (AEs), such as nausea, are reported by investigators rather than by pat

177 dose-limiting toxicities (DLTs): grade (G) 2 nausea at 120 mg; G3 fatigue at 250 mg; G2 nausea and G4

178 artburn at 3 months, odynophagia at 1 month, nausea at 3 and 12 months, wheezing at 6 months; and ina

179 Aprepitant did not reduce symptoms of nausea, based on the primary outcome measure (46% reduct

180 tenuates cisplatin-induced pica (a proxy for nausea/behavioral malaise in nonvomiting laboratory rode

181 laboratory adverse events were diarrhoea and nausea, both of which occurred in 15 (6%) patients.

182 e nicotine patch for vivid dreams, insomnia, nausea, constipation, sleepiness, and indigestion.

183 intention-to-treat analysis was reduction in nausea, defined as a decrease of 25 mm or more, or absol

184 roximately 17% of the participants, included nausea, diarrhea, and vomiting, and were mild in severit

185 lated adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting.

186 events were headache, fatigue, diarrhea, and nausea; diarrhea and nausea were reported more frequentl

187 roup 2 with all patients (100%) experiencing nausea, diarrhoea, abdominal bloating, and weight loss g

188 e often with dulaglutide than glargine, were nausea, diarrhoea, and vomiting.

189 Serious adverse events included severe nausea during surgery (1 patient), suicide attempt (4 pa

190 ents included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema; adverse events

191 ignificantly between the two groups included nausea (eight [7%] vs one [<1%]), vomiting (13 [11%] vs

192 stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, whereas edem

193 ncluding thyroid toxicity, thrombocytopenia, nausea, fatigue, jaundice, and muscle aches.

194 Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorie

195 erse events associated with savolitinib were nausea, fatigue, vomiting, and peripheral edema.

196 (eight [12%] of 65 vs four [12%] of 33) and nausea (five [8%] of 65 vs four [12%] of 33).

197 41 there was an increased incidence of early nausea for patients given irinotecan plus oxaliplatin (I

198 d chills, decreased appetite, diarrhoea, and nausea (four each; 33%).

199 disorder (nine patients), mild and transient nausea (four patients), and transient headache (four pat

200 testinal symptoms (abdominal pain, bloating, nausea, gas, and fullness) before breakfast and every 30

201 iting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]).

202 miting (grade 3: 47 [3%] vs five [<1%]), and nausea (grade 3: 26 [2%] vs two [<1%]).

203 hrombotic thrombocytopenic purpurea, grade 2 nausea, grade 2 generalised muscle weakness, grade 2 inf

204 rvation (grade 4 maculopapular rash, grade 3 nausea, grade 3 infection, grade 3 thrombotic thrombocyt

205 reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interrupti

206 events (incidence 5%) for vortioxetine were nausea, headache, and diarrhea.

207 The most frequent adverse events were nausea, headache, and fatigue (12-week arm: 15% [23/155]

208 uently reported adverse events were fatigue, nausea, headache, insomnia, and rash.

209 s included anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hypophosphatemia, and anorex

210 e events (eg, lethargy, diarrhoea, rash, and nausea) improved during the first 3 months of de-escalat

211 We calculated relative risks of nausea improvement using stratified Cochran-Mental-Haens

212 Other common adverse events were nausea in (14 [23%] patients in MPa100Z group, 8 [13%] p

213 Diarrhea in 55% of courses and nausea in 54% of courses were the most common nonhematol

214 ld be evident between subjects who developed nausea in comparison to those who did not.

215 hema in both groups and minor infections and nausea in the combination therapy group.

216 driven by a higher incidence of drug-related nausea in the dolutegravir, abacavir, and lamivudine gro

217 ing was common in the misoprostol group, and nausea in the oxytocin group.

218 sis in two (4%), hypercalcaemia in two (4%), nausea in two (4%), and cutaneous squamous cell carcinom

219 encing diarrhoea in three patients (50%) and nausea in two patients (33%) and in group 2 with all pat

220 upper respiratory tract infection (in 48%), nausea (in 47%), and grade 3 or 4 neutropenia (in 41%).

221 erase (114 [60%]) in the ceritinib group and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]

222 ommon study drug-related adverse events were nausea (in ten participants), abdominal pain (in six), a

223 emonstrates that the subjective sensation of nausea is associated with objective changes in autonomic

224 dose-related gastrointestinal side effects (nausea, loose stools, vomiting) were common but did not

225 (MST) score, 3-d food records, postoperative nausea, LOS, and complications.

226 tion in average meal size and independent of nausea/malaise.

227 mptoms in the first month of cancer therapy: nausea (n = 109; 84.5%), loss of appetite (n = 97; 75.2%

228 rade 3 to 4 events were neutropenia (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis

229 ts attributed to X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevat

230 thema (n=10 [12%] and n=0, respectively) and nausea (n=2 [2%] and n=11 [12%], respectively).

231 atigue or weakness (n=495, 68%), vomiting or nausea (n=365, 50%), and diarrhoea (n=294, 41%) were the

232 spoglutide, 20 mg, had the greatest risk for nausea (odds ratios, 1.9 to 5.9).

233 hyperglycaemia (two [4%] patients, grade 3), nausea (one [2%], grade 3), hypoglycaemia (one [2%], gra

234 challenge test, she felt abdominal pain and nausea only after eating fruit, along with the albedo, o

235 f high plasma drug levels without associated nausea or emesis.

236 Nausea or vomiting occurred more frequently in the sertr

237 and >30% reduction in PTH) and self-reported nausea or vomiting.

238 enia, diarrhea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at admission.

239 raction effects for bloating (P = .005), and nausea (P = .02), and a nonsignificant trend was found f

240 n (P-treatment x time interaction < 0.0001), nausea (P-treatment x time interaction < 0.05), and bloa

241 Nausea prevention was the primary end point; a complete

242 ompared with placebo, significantly improved nausea prevention, as well as the complete-response rate

243 recovery from ON, bilateral ON, intractable nausea, progressive course of disability), laboratory re

244 ommon adverse events were fatigue, headache, nausea, rash, and insomnia.

245 finding that may provide insight into other nausea-related phenotypes like PONV.

246 ogical mechanisms involved in the genesis of nausea remains lacking.

247 aspoglutide, 20 mg, had the highest risk for nausea; risk for hypoglycemia among once-weekly GLP-1RAs

248 ng safety, oseltamivir increased the risk of nausea (RR 1.60, 95% CI 1.29-1.99; p<0.0001; 9.9% oselta

249 The mean nausea score on the Visual Analogue Scale (score 0-10) w

250 d that ondansetron was associated with lower nausea scores on day 4 than metoclopramide (mean visual

251 Although there was no difference in trend in nausea scores over the 14-day study period, trend in vom

252 were stratified into quartiles based on VAS nausea scores, with the upper and lower quartiles consid

253 e upper and lower quartiles considered to be nausea sensitive and resistant, respectively.

254 Furthermore, nausea-sensitive subjects had decreased plasma ghrelin a

255 During the motion video, nausea-sensitive subjects had lower normogastria/tachyga

256 ported 0-to-100 visual analog scale (VAS) of nausea severity.

257 -week group; 14 [23%] in the 16-week group), nausea (six [10%] in the 12-week group; eight [13%] in t

258 mmon adverse event were fatigue (six [24%]), nausea (six [24%]), and arthralgia (five [20%]).

259 Most common adverse events (AEs) included nausea, skin and subcutaneous tissue disorders (SSTD), d

260 sleep disturbances, drowsiness or tiredness, nausea, sweating, and being restless or overactive) did

261 rst decade of life, and subjective symptoms (nausea, throat tightness, and dizziness) were prevalent

262 tients vs no patients in the placebo group), nausea (two [2%] vs none), and hyperglycaemia (two [2%]

263 ea (two patients), fatigue (three patients), nausea (two patients), and upper respiratory infections

264 quent adverse events by treatment group were nausea (varenicline, 25% [511 of 2016 participants]), in

265 d upper abdominal discomfort for two months; nausea, vomiting or weight loss were not reported.

266 Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were as

267 ure, and presents itself in association with nausea, vomiting, and abnormal sensitivity to light, noi

268 cancers despite severe side effects such as nausea, vomiting, and anorexia that compromise quality o

269 Nausea, vomiting, and diarrhea were more common in the a

270 most frequent adverse events were low-grade nausea, vomiting, and diarrhea.

271 recognize the early signs of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3%

272 ear-old female, professional diver, reported nausea, vomiting, and systemic hives 20 to 30 minutes af

273 ther common clinical features include fever, nausea, vomiting, and tinnitus.

274 ncluding epigastric pain, postprandial pain, nausea, vomiting, and weight loss.

275 g-related adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well

276 ffects that devastate quality of life (e.g., nausea, vomiting, anorexia, weight loss).

277 ion 4.0 definitions of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, dia

278 and physicians of six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and hair loss)

279 move the IGBs from the patient's body causes nausea, vomiting, discomfort, and even gastric mucous da

280 erences between treatment arms with postdose nausea, vomiting, or other adverse events.

281 e peripheral nervous system, such as chronic nausea, vomiting, pain, and hypertension.

282 cope, focal neurologic deficits, chest pain, nausea, vomiting, unintentional weight loss, or recent t

283 dysphagia (P = .0012), GERD (P = .0001), and nausea/vomiting (P < .0001).

284 ropenia [54% vs 23%; P < .001] and grade 3/4 nausea/vomiting [20% vs 11%; P = .03]), while rates of g

285 charge; and 6 of 23 [26.1%] for incidence of nausea/vomiting in the PACU).

286 cisions to withhold opioids when ADEs (i.e., nausea/vomiting or oversedation) were present together w

287 few indications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pai

288 Women reporting nausea/vomiting were less likely to be adherent in both

289 gia, gastroesophageal reflux disease [GERD], nausea/vomiting, and pain) align with clinical symptomol

290 Nausea was a predictor of protein intake.

291 Nausea was greater in both groups with exenatide, but su

292 Treatment-related nausea was more common in the OXN PR group than in the p

293 tide groups were gastrointestinal in nature: nausea was reported in 26 (20%) who received 0.5 mg sema

294 ion of patients with no chemotherapy-induced nausea was significantly greater with olanzapine than wi

295 Nausea was the most common adverse event in the liraglut

296 fatigue, diarrhea, and nausea; diarrhea and nausea were reported more frequently by patients receivi

297 led jellyfish product (100g), he experienced nausea, wheezing, and erythema and had visited our hospi

298 e, aprepitant did not reduce the severity of nausea when reduction in VAS score was used as the prima

299 was mostly similar between groups except for nausea, which occurred less frequently in patients given

300 However, adverse events, postdose nausea with high-dose azithromycin, effectiveness of sin

301 most frequently reported adverse events were nausea with semaglutide, reported in 77 (21%) patients w